A new report highlights promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopaecia, multiple myeloma and breast cancer on the horizon, with personalised medicines strongly represented. Analysts Clarivate have identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1 billion within five years. These promising advancements include […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!